Revance Therapeutics Inc (NAS:RVNC)
$ 2.7 -0.2 (-6.9%) Market Cap: 282.01 Mil Enterprise Value: 480.72 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 59/100

Revance Therapeutics Inc at Guggenheim Healthy Altitudes Summit Transcript

Mar 16, 2023 / 01:45PM GMT
Release Date Price: $31.15 (+1.63%)
Seamus Fernandez
Guggenheim Securities - Analyst

All right. Thanks, everybody. So we're joined by Toby Schilke. In a second, we're going to talk about Revance Therapeutics. A little bit of a break from the biotech high science thought process and moving into really what I think is probably one of the more exciting consumer opportunities and biotech product launches that we're going to see over the next, probably year or so.

So Toby, thanks for joining us. Love to just -- maybe you can kick us off and remind people, remind everybody here what Revance is all about on the aesthetic side and then also there's the therapeutic opportunity.

Toby Schilke
Revance Therapeutics, Inc. - CFO

Thanks, Seamus. So yeah, we were approved last September for DAXXIFY, which is launching into a relatively mature market in facial aesthetics. Companies have been around there for two decades, dominated by Allergan with three other approved products in the treatment of glabellar lines. This is a cash-pay market and really dominated by Allergan.

However, DAXXIFY has

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot